Evidence map›Paper›PMID 31117525›Full record

ArticleJournal of natural products2019

Baraphenazines A-G, Divergent Fused Phenazine-Based Metabolites from a Himalayan Streptomyces.

Xiachang Wang, Muhammad Abbas, Yinan Zhang, Sherif I Elshahawi, Larissa V Ponomareva, Zheng Cui, Steven G Van Lanen, Imran Sajid, S Randal Voss, Khaled A Shaaban and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of natural products, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. NewTheScientificWorldJournal · 2025
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. OleD Loki as a Catalyst for Hydroxamate Glycosylation.Chembiochem : a European journal of chemical biology · 2020
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Xiachang WangJiangsu Key Laboratory for Functional Substances of Chinese Medicine , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.ORCID 0000-0002-1106-1904
Muhammad AbbasDepartment of Microbiology and Molecular Genetics , University of the Punjab , Quid-i-Azam campus, Lahore 54590 , Pakistan.
Yinan ZhangJiangsu Key Laboratory for Functional Substances of Chinese Medicine , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.ORCID 0000-0002-0362-1473
Sherif I ElshahawiDepartment of Biomedical and Pharmaceutical Sciences , Chapman University School of Pharmacy , Irvine , California 92618 , United States.ORCID 0000-0003-1879-1552
Larissa V Ponomareva
Zheng Cui
Steven G Van LanenORCID 0000-0003-1539-2732
Imran SajidDepartment of Microbiology and Molecular Genetics , University of the Punjab , Quid-i-Azam campus, Lahore 54590 , Pakistan.ORCID 0000-0002-4781-1455
S Randal Voss
University of Kentucky · USNanjing University of Chinese Medicine · CNUniversity of the Punjab · PKChapman University · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
Training in Drug Abuse Related Research.T32DA016176 · NIDA · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P · 2004 to 2020
$4.0M
Developing Regeneration Resources for a Model AmphibianR24OD021479 · OD · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT, VOSS, STEPHEN RANDAL · 2016 to 2019
$2.3M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NIDA NIH HHS T32 DA016176NIH HHS R24 OD021479
6 · The paper itself

Abstract

The structures and bioactivities of three unprecedented fused 5-hydroxyquinoxaline/alpha-keto acid amino acid metabolites (baraphenazines A-C, 1-3), two unique diastaphenazine-type metabolites (baraphenazines D and E, 4 and 5) and two new phenazinolin-type (baraphenazines F and G, 6 and 7) metabolites from the Himalayan isolate Streptomyces sp. PU-10A are reported. This study highlights the first reported bacterial strain capable of producing diastaphenazine-type, phenazinolin-type, and izumiphenazine A-type metabolites and presents a unique opportunity for the future biosynthetic interrogation of late-stage phenazine-based metabolite maturation.

Indexed as

Anti-Bacterial AgentsMolecular StructurePhenazinesQuinoxalinesStreptomycesAnti-Bacterial AgentsPhenazinesQuinoxalines

Identifiers

PMID31117525
PMCPMC6630045
OpenAlexW2946979094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.